SCHEMBL5879200

SCHEMBL5879200

Cc1ccc2c(C3=CC(=O)NC3=O)c[nH]c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 5/20 0.46
CCND1 P24385 5/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
IDO1 P14902 1/20 0.43
NR4A2 P43354 1/20 0.41
PRKCB P05771 3/20 0.41
HTR2A P28223 1/20 0.40
CCNE2 O96020 3/20 0.40
CCNE1 P24864 3/20 0.40
CDK2 P24941 3/20 0.40
PRKACA P17612 2/20 0.40
PRKACG P22612 2/20 0.40
PRKACB P22694 2/20 0.40
CAMK2D Q13557 2/20 0.40
PRKD3 O94806 1/20 0.40
CCNB2 O95067 1/20 0.40
ABL1 P00519 1/20 0.40
PRKCG P05129 1/20 0.40
CDK1 P06493 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879259 0.88 KDM4E (0.44) CDK4CCND1MEN1KMT2AIDO1
SCHEMBL5879258 0.82 CDK4 (0.49) CDK4CCND1IDO1CCNE2CCNE1
SCHEMBL5879143 0.82 IDH1 (0.46) CDK4CCND1IDO1NR4A2PRKCB
SCHEMBL5879319 0.82 CDK4 (0.49) CDK4CCND1IDO1PRKCBCCNE2
SCHEMBL5879260 0.82 CDK4 (0.71) CDK4CCND1MEN1KMT2APRKCB
SCHEMBL22566997 0.81 CDK4 (0.66) CDK4CCND1MEN1KMT2AIDO1
SCHEMBL2193383 0.78 PRKCB (0.65) CDK4CCND1PRKCBCCNE2CCNE1
SCHEMBL29771997 0.78 PRKCB (0.65) CDK4CCND1PRKCBCCNE2CCNE1
SCHEMBL9086873 0.75 PRKCB (0.74) CDK4CCND1PRKCBCCNE2CCNE1
SCHEMBL5879251 0.75 CDK4 (0.45) CDK4CCND1CDK2ABL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CDK4 1989/4885CCND1 405/4885MEN1 3629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.